Pharma must improve existing methods to boost solubility as “quantum leap” unlikely

By Nick Taylor

- Last updated on GMT

Related tags: Improve, Ceo

To boost solubility pharma must develop, refine and improve existing methods as a “quantum leap” in formulation is unlikely, Pharmaterials' CEO said.

Interest in boosting bioavailability has risen as compounds coming through development pipelines have become less soluble. However, improvements to formulation are expected to be gradual.

I don’t think I have seen a dramatically new approach to this. We will develop them, refine, improve, but perhaps not [make] a quantum leap​”, Graham Buckton, CEO of Pharmaterials, a subsidiary of Pii, and professor at the London School of Pharmacy, told in-PharmaTechnologist.

Pharma companies are likely to be receptive to improved techniques. Buckton gave the example of amorphous formulations which were around for decades before being used frequently by industry.

It’s become acceptable out of necessity I imagine​”, Buckton said.

Related news

Show more

Related products

show more

A Better Approach, for Better Pain Trials

A Better Approach, for Better Pain Trials

Signant Health | 27-Sep-2021 | Technical / White Paper

Pain studies face unique challenges. For one, pain severity can only be truly assessed by the patients themselves. The controlled substances that are often...

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Related suppliers

Follow us

Products

View more

Webinars